Specialist Updates 
Oncology

Better overall survival with checkpoint inhibitor: cervical cancer trial

Results from the KEYNOTE-826 trial in women with metastatic disease
Reuters Health
0
27 September 2021
Save
ClosePlease login
woman's hand. IV drip.

The checkpoint inhibitor, pembrolizumab, increases overall survival by 36% in patients with persistent, recurrent or metastatic cervical cancer, according to trial results.

The results of the KEYNOTE-826 trial carried out at 151 centres in 19 countries were announced at the European Society for Medical Oncology Congress in September and simultaneously published in The New England Journal of Medicine.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .